|
| Authors (year) | Study type | TKI drug type | Number of patients | Tumor type | Patients with hypothyroidism (↑TSH) (%) | Patients with isolated suppressed TSH (%) | Patients with suppressed TSH prior to elevated TSH (%) |
|
Rini et al.
[15] (2007) | Retrospective | Sunitinib | 66 | RCC | 56 (85%) | None | None |
|
Wong et al.
[16] (2007) | Retrospective | Sunitinib | 40 | Solid (mostly GIST) | 21 (53%) | None | None |
|
Desai et al.
[14] (2006) | Prospective | Sunitinib | 42 | GIST | Persistent = 15 (36%)
Transient = 7 (17%) | 4 (10%) | 6 (14%) |
|
Mannavola et al.
[17] (2007) | Prospective | Sunitinib | 24 | GIST | Total = 17 (71%)
Persistent = 11 (46%) | None | None |
|
Wolter et al.
[18] (2008) | Prospective | Sunitinib | 59 | RCC, GIST | Total = 36 (61%)
16 (27%) required thyroid hormone treatment
20 (34%) did not require thyroid hormone treatment | None | None |
|
Shinohara et al.
[19] (2011) | Prospective | Sunitinib | 17 | RCC | 8 (47%) | None | None |
|
Tamaskar et al.
[21] (2008) | Retrospective | Sorafenib | 39 | RCC | 7 (18%) | 1 (2.6%) | None |
|
Clement et al.
[22] (2008) | Prospective | Sorafenib | 38 | RCC | 7 (30%) | 1 (5%) | None |
|
Schmidinger et al.
[23] (2011) | Prospective | Sunitinib or sorafenib | 87 | RCC | 5 (5.7%) subclinical hypothyroidism in 30 patients (36.1%) after 2 months of treatment | None | None |
|
Riesenbeck et al.
[24] (2011) | | Sunitinib or sorafenib | 66 | RCC | 21 (31.8%) | None | None |
|
de Groot et al.
[25] (2007) | Prospective | Imatinib | 11 | MTC, GIST | 8 out of 8 patients with previous thyroidectomies had increased thyroid hormone requirement Other patients were euthyroid | None | None |
|
de Groot et al.
[26] (2005) | Prospective | Imatinib | 15 | MTC | 9 out of 10 patients with previous thyroidectomies had increased thyroid hormone requirement Other patients were euthyroid | None | None |
|
Kim et al.
[27] (2010) | Prospective | Nilotinib | 55 | Ph-positive
CML | Total = 12 (22%)
Transient = 8 (15%)
Persistent = 4 (7%) | Total = 18 (33%)
Transient = 15 (27%)
Persistent = 3 (5%) | None |
|
Sherman et al.
[35] (2008) | Prospective | Motesanib diphosphate | 99 | DTC | 17 (22%) (all patients athyreotic) | None | None |
|
Robinson et al.
[36] (2010) | Prospective | Vandetanib | 19 | MTC | Mean 5.1-fold increase in TSH in 17 patients with available TFTs | None | None |
|
Robinson et al.
[36] (2010) | Prospective | Axitinib | 18 | Solid tumors | 16 (89%) | None | None |
|
Ohba et al.
[28] (2013) | Prospective | Axitinib | 6 | Metastatic renal cell carcinoma | 5 (83%) | 1 (16%) | 4 (66.6%) |
|
Fujiwara et al.
[29] (2012) | Prospective | Axitinib | 18 | Advanced solid tumors | 16 (89%) | None | None |
|
Mukohara et al.
[30] (2010) | Prospective | Axitinib | 12 | Advanced solid tumors | 11 (92%) | None | None |
|
Wolter et al.
[32] (2011) | Prospective | Pazopanib | 578 | Renal cell carcinoma | Elevated TSH at baseline (>5 MU/L) was 37 (6%).
167 (29%) patients had a TSH value of >5 MU/L during treatment;
97 (17%) patients had TSH values of >5–10 MU/L during treatment;
45 (8%) patients had TSH values of >10–20 MU/L; and 25 (4%) patients had TSH values of >20 MU/L. Hypothyroidism (TSH > 5–10 MU/L, and T4 < LLN) was observed in 19 (3%) patients. Hypothyroidism with TSH > 10 MU/L and T4 < LLN was diagnosed in 15 (3%) patients | Hyperthyroidism, defined as TSH < 0.3 MU/L and T4 > ULN, was seen in 8 (1%) patients | None |
|
|
Sherman et al. [35] (2008) | Prospective (phase III trial) | Pazopanib | 202 | Locally advanced or metastatic renal cell carcinoma | <10% | None | None |
|
| Motzer [34] (2013) | Prospective (phase III trial) | Tivozanib | 260 | Advanced renal cell carcinoma | Preliminary results: the incidence of hypothyroidism was higher in the tivozanib arm (13 subjects, 5.0%) than in the sorafenib arm (6 subjects, 2.3%) | None | None |
|
